Inter- and intratumoral heterogeneity in nano-drug uptake and efficacy is recognized.
The link between delivery and efficacy of nanomedicines depends on formulation and tumor properties.
Tumor metrics beyond bulk uptake are proposed as determinants of nanomedicine efficacy.
Spatio-temporal measurements of tumor properties are required pre- and post-treatment.